The Shotlee Journal
Browse Shotlee articles about Metabolic Health.
Showing 9 / 741 Metabolic Health articles
GLP-1 medications like semaglutide and tirzepatide deliver impressive weight loss, but what happens when you stop? Pivotal trials reveal significant regain risks, underscoring obesity as a chronic condition. This guide breaks down the evidence and offers practical insights for sustained results.
A recent Danish study in JAMA Internal Medicine highlights higher kidney risks with popular GLP-1 drugs like Ozempic compared to SGLT2 inhibitors. While GLP-1s offer weight loss benefits, understanding these findings is crucial for patients. Learn the science, risks, and how to protect your kidneys.
GLP-1 medications like Ozempic and Wegovy promise dramatic weight loss, but new studies reveal a catch: most users regain weight within 1-2 years of stopping. High costs and side effects add to the burden, prompting interest in permanent alternatives. Learn the facts to make informed choices for your metabolic health.
Poison control calls for GLP-1 medications have skyrocketed, with children accidentally injecting drugs like Mounjaro leading to severe vomiting and hospitalization. This guide breaks down the risks, what happens in an overdose, and proven prevention strategies. Stay informed to protect your family while benefiting from these powerful weight loss tools.
Noticeable weight loss often leads to whispers: 'Are you on Ozempic?' GLP-1 medications like Ozempic and Wegovy are transforming bodies and conversations. Learn when it's appropriate to ask, drawing from medical experts and real patient experiences.
Over 11,600 people in Norfolk and Waveney may soon access Mounjaro on the NHS for weight loss. This guide breaks down eligibility, timelines, and clinical evidence behind tirzepatide's effectiveness. Learn how this dual GLP-1/GIP agonist stands out in metabolic health.
Alzheimer's disease may be more than just amyloid plaques—emerging evidence points to brain insulin resistance as a core driver, earning it the label 'Type 3 diabetes.' A recent Polish study uncovers how impaired insulin signaling starves neurons of energy and accelerates toxic protein buildup. Discover the science and potential therapies like GLP-1 agonists that could change the game.
Roche is advancing CT-388, a dual GLP-1/GIP agonist, after Phase 2 results showed impressive weight loss comparable to Eli Lilly's Zepbound. With the obesity market booming, can this injectable stand out against Wegovy and emerging orals? Dive into the data and what it means for patients.
Stopping Ozempic or Wegovy often leads to significant weight regain within 1-1.5 years, reversing gains in blood sugar, pressure, and cholesterol. Experts explain the science behind this, from metabolic adaptation to surging appetite. Understand how to approach GLP-1 therapy for long-term success.
